A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

This study is testing a new oral medication called D3S-002 to see if it is safe and effective for treating advanced solid tumors. It focuses on tumors that have specific genetic changes, known as MAPK pathway mutations, which help cancer cells grow.

This study is for adults with advanced solid tumors, including certain types of non-small cell lung cancer, that have specific genetic mutations. Participants must have these mutations confirmed in their tumor or blood and meet general health criteria to ensure the study is safe for them.

If you join, you will take the experimental drug daily in 21-day cycles. Doctors will monitor your health very closely throughout the study to check how your body reacts to the treatment and to determine the best dose.

This study is currently recruiting patients at medical centers in Detroit, Michigan; New York, New York; and Nashville, Tennessee. You can talk with your doctor to see if one of these locations is a good fit for you.